12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
| 应用 | 稀释度 |
|---|---|
| ELISA | 0.305-5000 ng/ml |
Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.
Immobilized human PD-1 at 0.5 μg/ml (50 μL/well) can bind to Nivolumab with a linear range of 0.305 ng/ml-5 μg/ml.
您现在的位置：